Showing results (1-10 of 415) with videos related to
Sort By:
Pageof 42
Best Practice & Research. Clinical Haematology|June 20, 2006
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapyJason Gotlib, N C P Cross, D Gary GillilandBlood|April 9, 2004
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementJason Gotlib, Jan Cools, James M Malone, et al.Best Practice & Research. Clinical Haematology|August 26, 2003
FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitorsD Gary GillilandSeminars in Hematology|November 26, 2002
Molecular genetics of human leukemias: new insights into therapyD Gary GillilandCurrent Hematology Reports|December 22, 2004
Farnesyltransferase inhibitor therapy in acute myelogenous leukemiaJason GotlibCurrent Hematologic Malignancy Reports|September 26, 2015
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic MastocytosisJason GotlibAmerican Journal of Hematology|October 22, 2015
World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and managementJason GotlibActa Haematologica|July 5, 2005
Molecular classification and pathogenesis of eosinophilic disorders: 2005 updateJason GotlibHematology. American Society of Hematology. Education Program|December 9, 2022
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasmsJason GotlibPageof 42